The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options

International Journal of Obesity - Tập 38 Số 2 - Trang 163-169 - 2014
Lana Fani1, Seon Gyeong Bak1, Patric J. D. Delhanty2, Elisabeth F. C. van Rossum2, Erica L.T. van den Akker1
1Department of Pediatrics, Division of Endocrinology, Erasmus MC, Rotterdam, The Netherlands.
2Department of Internal Medicine, Division of Endocrinology, Erasmus MC, Rotterdam, The Netherlands

Tóm tắt

Từ khóa


Tài liệu tham khảo

Withrow D, Alter DA . The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev 2011; 12: 131–141.

Skidmore PM, Yarnell JW . The obesity epidemic: prospects for prevention. QJM 2004; 97: 817–825.

Qi L, Cho YA . Gene-environment interaction and obesity. Nutr Rev 2008; 66: 684–694.

Moore CJ, Cunningham SA . Social position, psychological stress, and obesity: a systematic review. J Acad Nutr Diet 2012; 112: 518–526.

Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS . Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 1999; 20: 68–100.

Hess S, Linde Y, Ovadia O, Safrai E, Shalev DE, Swed A et al. Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity. J Med Chem 2008; 51: 1026–1034.

van den Berg L, Glorie-Docter M, van den Akker E, Delemarre-van de Waal HA . Obesity caused by melanocortin-4 receptor mutations. Ned Tijdschr Geneeskd 2012; 156: A4548.

Rene P, Le Gouill C, Pogozheva ID, Lee G, Mosberg HI, Farooqi IS et al. Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity. J Pharmacol Exp Ther 2010; 335: 520–532.

Farooqi IS . Monogenic human obesity. Front Horm Res 2008; 36: 1–11.

Hansen MJ, Schioth HB, Morris MJ . Feeding responses to a melanocortin agonist and antagonist in obesity induced by a palatable high-fat diet. Brain Res 2005; 1039: 137–145.

Getting SJ . Targeting melanocortin receptors as potential novel therapeutics. Pharmacol Ther 2006; 111: 1–15.

Ye Z, MacNeil T, Weinberg DH, Kalyani RN, Tang R, Strack AM et al. Structure-activity relationship of linear tetrapeptides Tic-DPhe-Arg-Trp-NH2 at the human melanocortin-4 receptor and effects on feeding behaviors in rat. Peptides 2005; 26: 2017–2025.

He S, Ye Z, Dobbelaar PH, Sebhat IK, Guo L, Liu J et al. Spiroindane based amides as potent and selective MC4R agonists for the treatment of obesity. Bioorg Med Chem Lett 2010; 20: 4399–4405.

He S, Ye Z, Dobbelaar PH, Bakshi RK, Hong Q, Dellureficio JP et al. Discovery of highly potent and efficacious MC4R agonists with spiroindane N-Me-1,2,4-triazole privileged structures for the treatment of obesity. Bioorg Med Chem Lett 2010; 20: 6524–6532.

Krishna R, Gumbiner B, Stevens C, Musser B, Mallick M, Suryawanshi S et al. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther 2009; 86: 659–666.

Hong Q, Bakshi RK, Palucki BL, Park MK, Ye Z, He S et al. Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist. Bioorg Med Chem Lett 2011; 21: 2330–2334.

Benoit SC, Schwartz MW, Lachey JL, Hagan MM, Rushing PA, Blake KA et al. A novel selective melanocortin-4 receptor agonist reduces food intake in rats and mice without producing aversive consequences. J Neurosci 2000; 20: 3442–3448.

Conde-Frieboes K, Ankersen M, Breinholt J, Hansen BS, Raun K, Thogersen H et al. Serendipitous discovery of a new class of agonists for the melanocortin 1 and 4 receptors and a new class of cyclophanes. Bioorg Med Chem Lett 2011; 21: 1459–1463.

Al-Barazanji KA, Miller JE, Rice SQ, Arch JR, Chambers JK . C-terminal fragments of ACTH stimulate feeding in fasted rats. Horm Metab Res 2001; 33: 480–485.

Cepoi D, Phillips T, Cismowski M, Goodfellow VS, Ling N, Cone RD et al. Assessment of a small molecule melanocortin-4 receptor-specific agonist on energy homeostasis. Brain Res 2004; 1000: 64–71.

Chen C, Jiang W, Tran JA, Tucci FC, Fleck BA, Markison S et al. Identification and characterization of pyrrolidine diastereoisomers as potent functional agonists and antagonists of the human melanocortin-4 receptor. Bioorg Med Chem Lett 2008; 18: 129–136.

Kumar KG, Sutton GM, Dong JZ, Roubert P, Plas P, Halem HA et al. Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice. Peptides 2009; 30: 1892–1900.

Hsiung HM, Hertel J, Zhang XY, Smith DP, Smiley DL, Heiman ML et al. A novel and selective beta-melanocyte-stimulating hormone-derived peptide agonist for melanocortin 4 receptor potently decreased food intake and body weight gain in diet-induced obese rats. Endocrinology 2005; 146: 5257–5266.

Hsiung HM, Smiley DL, Zhang XY, Zhang L, Yan LZ, Craft L et al. Potent peptide agonists for human melanocortin 3 and 4 receptors derived from enzymatic cleavages of human beta-MSH(5-22) by dipeptidyl peptidase I and dipeptidyl peptidase IV. Peptides 2005; 26: 1988–1996.

Wessells H, Hruby VJ, Hackett J, Han G, Balse-Srinivasan P, Vanderah TW . MT-II induces penile erection via brain and spinal mechanisms. Ann N Y Acad Sci 2003; 994: 90–95.

Kievit P, Halem H, Marks DL, Dong JZ, Glavas MM, Sinnayah P et al. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes 2013; 62: 490–497.

Linde Y, Ovadia O, Safrai E, Xiang Z, Portillo FP, Shalev DE et al. Structure-activity relationship and metabolic stability studies of backbone cyclization and N-methylation of melanocortin peptides. Biopolymers 2008; 90: 671–682.

Granell S, Mohammad S, Ramanagoudr-Bhojappa R, Baldini G . Obesity-linked variants of melanocortin-4 receptor are misfolded in the endoplasmic reticulum and can be rescued to the cell surface by a chemical chaperone. Mol Endocrinol 2010; 24: 1805–1821.

Ward KR, Bardgett JF, Wolfgang L, Stocker SD . Sympathetic response to insulin is mediated by melanocortin 3/4 receptors in the hypothalamic paraventricular nucleus. Hypertension 2011; 57: 435–441.

Roubert P, Dubern B, Plas P, Lubrano-Berthelier C, Alihi R, Auger F et al. Novel pharmacological MC4R agonists can efficiently activate mutated MC4R from obese patient with impaired endogenous agonist response. J Endocrinol 2010; 207: 177–183.

Raun K, Dahl K, Nilsson C, Voss PV, Fosgerau K, Conde-Frieboes KW et al. Novel MC4 agonist peptide effectively reduces body weight in diet-induced obese rats and minipigs. Obesity 2011; 19: S179.

Raun K, Conde-Frieboes KW, Sensfuss U, Wulff BS . A long acting, selective MC4 receptor agonist effectively reduces appetite and bodyweight in diet induced obese rats. Obes Rev 2011; 12: 279.

Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C . The FDA’s assessment of two drugs for chronic weight management. N Engl J Med 2012; 367: 1577–1579.

Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363: 245–256.